Amicus Therapeutics (FOLD) Non-Current Deferred Tax Liability: 2013-2022
Historic Non-Current Deferred Tax Liability for Amicus Therapeutics (FOLD) over the last 9 years, with Dec 2022 value amounting to $4.9 million.
- Amicus Therapeutics' Non-Current Deferred Tax Liability rose 0.18% to $4.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.9 million, marking a year-over-year increase of 0.18%. This contributed to the annual value of $4.9 million for FY2022, which is 0.18% up from last year.
- Amicus Therapeutics' Non-Current Deferred Tax Liability amounted to $4.9 million in Q4 2022, which was up 0.18% from $4.9 million recorded in Q3 2022.
- Over the past 5 years, Amicus Therapeutics' Non-Current Deferred Tax Liability peaked at $6.5 million during Q1 2018, and registered a low of $4.9 million during Q4 2020.
- In the last 3 years, Amicus Therapeutics' Non-Current Deferred Tax Liability had a median value of $4.9 million in 2022 and averaged $4.9 million.
- Per our database at Business Quant, Amicus Therapeutics' Non-Current Deferred Tax Liability plummeted by 96.28% in 2018 and then increased by 0.69% in 2021.
- Over the past 5 years, Amicus Therapeutics' Non-Current Deferred Tax Liability (Quarterly) stood at $6.5 million in 2018, then fell by 21.87% to $5.1 million in 2019, then fell by 3.07% to $4.9 million in 2020, then grew by 0.69% to $4.9 million in 2021, then rose by 0.18% to $4.9 million in 2022.
- Its Non-Current Deferred Tax Liability was $4.9 million in Q4 2022, compared to $4.9 million in Q3 2022 and $4.9 million in Q2 2022.